Ranbaxy Issues Allergy Drug Recall From Its Sole U.S.-Approved Plant
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories said it has ordered a recall of a batch of its loratadine generic allergy drug made at its only plant allowed to supply drugs in the U.S., its Ohms Laboratories unit.
Ranbaxy Laboratories said it has ordered a recall of a batch of its loratadine generic allergy drug made at its only plant allowed to supply drugs in the U.S., its Ohms Laboratories unit. The issue, Ranbaxy said, was defective packaging that allowed an unacceptable level of defects in the 29,790 blister packs produced in February. The voluntary recall was announced by the U.S. FDA, which has banned imports of drugs from Ranbaxy's four plants in India. (Click here for more
)
"Ranbaxy Recalls Anti-Allergy Drug In U.S." - Delhi Daily News (India) (5/3/2014)